Vimarsana
Biggest News Aggregation in the World

Page 3 - Alrn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alrn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alrn Today - Breaking & Trending Today

Aileron Therapeutics (ALRN) Set to Announce Quarterly Earnings on Monday - Vimarsana News

Aileron Therapeutics (ALRN) Set to Announce Quarterly Earnings on Monday

Aileron Therapeutics (NASDAQ:ALRN – Get Rating) is set to issue its quarterly earnings data on Monday, March 27th. Aileron Therapeutics Trading Up 2.9 % Shares of ALRN stock opened at $1.39 on Friday. Aileron Therapeutics has a 12-month low of $1.25 and a 12-month high of $15.00. The business’s 50 day moving average is $2.13 […]

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 39.6% in May - Vimarsana News

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 39.6% in May

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 197,300 shares, a decline of 39.6% from the May 15th total of 326,900 shares. Based on an average daily volume of 350,100 shares, the days-to-cover ratio is […]

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expected to Announce Earnings of -$0.09 Per Share - Vimarsana News

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expected to Announce Earnings of -$0.09 Per Share

Brokerages predict that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings of ($0.06) per share in the same quarter last year, which indicates a negative year-over-year […]

Aileron Therapeutics (NASDAQ:ALRN) Downgraded by Zacks Investment Research to "Sell" - Vimarsana News

Aileron Therapeutics (NASDAQ:ALRN) Downgraded by Zacks Investment Research to "Sell"

Aileron Therapeutics (NASDAQ:ALRN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. […]

-$0.09 EPS Expected for Aileron Therapeutics, Inc. (NASDAQ:ALRN) This Quarter - Vimarsana News

-$0.09 EPS Expected for Aileron Therapeutics, Inc. (NASDAQ:ALRN) This Quarter

Brokerages forecast that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics posted earnings per share of ($0.06) in the same quarter last year, which suggests a negative year over […]